Measuring “fearonomic effects” in valuing therapies: An application to COVID-19 in China

Date: July 27, 2020

Journal: Value in Health

Citation: Ma S, Kim DD, Cohen JT, Neumann PJ. "Measuring “fearonomic effects” in valuing therapies: An application to COVID-19 in China," Value in Health (in press).

More Publications

Perspective and costing in cost-effectiveness analysis, 1974–2018

View Publication

Crisis into opportunity: Can COVID-19 help set a path to improved health care efficiency?

View Publication

Patient characteristics and treatment patterns among Medicare beneficiaries initiating PCSK9 inhibitor therapy

View Publication

View All Publications